~50% of patients experience a CINV event despite use of guideline-recommended antiemetic regimens1
Data from a prospective observational study where 742 patients received guideline-adherent antiemetic treatment for single-day HEC or MEC at 4 oncology practice networks, all using EMR systems, in Georgia, Tennessee, and Florida.1
- CINV event defined as emesis or clinically significant nausea on days 1-5.
- Up to 50% of patients at 4 different community oncology practice networks across the US (n=742) still experienced a CINV event despite the use of guideline-recommended CINV regimens1
- The guideline-recommended HEC regimen included a 5-HT3 RA + NK1 RA + dexamethasone; the MEC regimen included a 5-HT3 RA + dexamethasone1
- 5-HT3 RA used: palonosetron (94%) or ondansetron (5%)1
Early control of CINV is important for future efficacy2
- Patients with uncontrolled CINV at cycle 1 had 4 times the rate of anticipatory CINV prior to cycle 23
- Antiemetics that provide broad coverage of acute and delayed CINV with proven efficacy should be preferred4
- Gilmore et al. J Oncol Pract. 2014.
- Schwartzberg et al. Am Health Drug Benefits. 2015.
- Aapro et al. Ann Oncol. 2006.
- Rapoport. Front Pharmacol. 2017.
- SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.